Catégorie : Cannabis therapeutique

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats, Leonardo B.M. Resstel et al., 2009

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats Leonardo B.M. Resstel, Rodrigo F. Tavares, Sabrina F.S. Lisboa, Sâmia R.L. Joca, Fernando M.A. Corrêa and Francisco S. Guimarães British Journal of Pharmacology, 2009, 156, 181–188; doi : 10.1111/j.1476-5381.2008.00046.x Background and purpose : Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa which induces anxiolytic- and antipsychotic-like effects in rodents. These effects could be mediated by facilitation of the endocannabinoid system or by the activation of 5-HT1A receptors. As either of these mechanisms could promote adaptation to inescapable stress, the aim of the present work [...]

Lire la suite

IACM-Bulletin du 13 Juin 2020

IACM-Bulletin du 13 Juin 2020 Science/Israël: Les anciens Israélites ont peut-être consommé du cannabis dans le cadre d'un rituel religieux il y a 3000 ans Science/Homme: Une étude ne trouve aucune preuve que la consommation de cannabis augmente le risque d'AVC Science/Homme: Les données scientifiques disponibles ne supportent pas l'hypothèse selon laquelle la consommation de cannabis peut augmenter l'accident du travail Science/Homme: La consommation de cannabis est associée à une réduction des symptômes chez les patients souffrant de trouble de stress post-traumatique Science/Homme: Selon une étude ouverte le cannabis peut être utile dans le traitement [...]

Lire la suite

Après la crise du Covid-19 il faut légaliser le cannabis, vite !, François-Michel LAMBERT député des Bouches du Rhône, 2020

Après la crise du Covid-19 il faut légaliser le cannabis, vite ! François-Michel LAMBERT député des Bouches du Rhône   En juin 2019 avec une vingtaine de députés nous déposions une proposition de loi, relative « à la légalisation contrôlée de la production, de la vente et de la consommation de cannabis ». La même semaine le « conseil d’analyse économique », think tank rattaché à Matignon, préconisait dans un rapport très documenté la légalisation du cannabis récréatif et une tribune dans l’Obs signée par 70 médecins, économistes et élus nationaux et locaux, plaidait pour cette légalisation. Ces initiatives pour la légalisation du cannabis dénoncent [...]

Lire la suite

PROPOSITION DE LOI relative à la légalisation contrôlée de la production, de la vente et de la consommation de cannabis, Assemblée Nationale, France, 2019

N° 2099 _____ ASSEMBLÉE NATIONALE CONSTITUTION DU 4 OCTOBRE 1958 QUINZIÈME LÉGISLATURE Enregistré à la Présidence de l’Assemblée nationale le 2 juillet 2019.   PROPOSITION DE LOI relative à la légalisation contrôlée de la production, de la vente et de la consommation de cannabis, (Renvoyée à la commission des affaires sociales, à défaut de constitution d’une commission spéciale dans les délais prévus par les articles 30 et 31 du Règlement.) présentée par Mesdames et Messieurs François-Michel LAMBERT, Delphine BAGARRY, Ugo BERNALICIS, Annie CHAPELIER, Stéphane CLAIREAUX, Jean-Michel CLÉMENT, Éric COQUEREL, Jeanine DUBIÉ, Frédérique DUMAS, Caroline FIAT, Caroline JANVIER, Régis JUANICO, Hubert JULIEN-LAFERRIÈRE, Danièle OBONO, Sébastien NADOT, Sylvia PINEL, Loïc PRUD’HOMME, Bénédicte TAURINE, François [...]

Lire la suite

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder, Emily M. LaFrance et al., 2020,

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132   A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]

Lire la suite

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial, Daryl Efron et al.,

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial Daryl Efron, Kaitlyn Taylor, Jonathan M Payne, Jeremy L Freeman, Noel Cranswick, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Katrina Williams BMJ Open, 2020, 10, e034362. doi : 10.1136/bmjopen-2019-034362   Abstract Introduction : Severe behavioural problems (SBPs) are a common contributor to morbidity and reduced quality of life in children with intellectual disability (ID). Current medication treatment for SBP is associated with a high risk of side effects. Innovative and safe interventions are urgently needed. Anecdotal reports and preliminary research suggest that medicinal [...]

Lire la suite

A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability, Daryl Efron et al., 2020

  A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability Daryl Efron, Jeremy L Freeman, Noel Cranswick, Jonathan M Payne, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Kaitlyn Taylor, Katrina Williams British Journal of Clinical Pharmacology, 2020 Jun 1. doi : 10.1111/bcp.14399. Abstract Introduction : Severe Behavioural Problems (SBP) are a major contributor to morbidity in children with Intellectual Disability (ID). Medications used to treat SBP in ID are associated with a high risk of side effects. Cannabidiol has potential therapeutic effects in SBP. This pilot study aimed to investigate the feasibility of conducting a randomized placebo-controlled [...]

Lire la suite

The nephrologist’s guide to cannabis and cannabinoids, Joshua L. Rein, 2020

The nephrologist’s guide to cannabis and cannabinoids Joshua L. Rein   Purpose of review Cannabis (marijuana, weed, pot, ganja, Mary Jane) is the most commonly used federally illicit drug in the United States. The present review provides an overview of cannabis and cannabinoids with relevance to the practice of nephrology so that clinicians can best take care of patients. Recent findings Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. Cannabis does not seem to affect kidney function in healthy individuals. However, renal function should be [...]

Lire la suite

New Data Show No Link Between Cannabis and Stroke Sue Hughes, Medscape.com, June 09, 2020

New Data Show No Link Between Cannabis and Stroke Sue Hughes Medscape.com, June 09, 2020 https://www.medscape.com/viewarticle/931988_print A new study that used admission urine toxicology tests to ascertain drug use found no independent association between recent cannabis use and the incidence of acute ischemic stroke. "Previous studies have shown conflicting data on cannabis use and stroke. Our study is a step forward in that we had quite a large population and we had an objective measure of marijuana use with the urine screen, whereas some previous studies have just relied on asking the patient about marijuana use," senior author Shreyas Gangadhara, MD, University of Mississippi Medical Center, Jackson, [...]

Lire la suite

Cannabis Misconceptions Still Common Among MS Clinicians, Nancy Melville, Medscape.com, 2020

Cannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1   Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]

Lire la suite